Want to see STRO full AI Analyst Report?
Total Valuation
Sutro Biopharma has a market cap or net worth of $527.60M. The enterprise value is $214.88M.
Market Cap$527.60M
Enterprise Value$214.88M
Share Statistics
Sutro Biopharma has 16,570,438 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding16,570,438
Owned by Insiders0.81%
Owned by Institutions<0.01%
Financial Efficiency
Sutro Biopharma’s return on equity (ROE) is 1.44 and return on invested capital (ROIC) is -98.52%.
Return on Equity (ROE)1.44
Return on Assets (ROA)-1.10
Return on Invested Capital (ROIC)-98.52%
Return on Capital Employed (ROCE)-1.06
Revenue Per Employee748.06K
Profits Per Employee-1.39M
Employee Count137
Asset Turnover0.59
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Sutro Biopharma is ―. Sutro Biopharma’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.96
PB Ratio-0.74
Price to Fair Value-0.74
Price to FCF-0.55
Price to Operating Cash Flow-0.03
PEG Ratio0.02
Income Statement
In the last 12 months, Sutro Biopharma had revenue of 102.48M and earned -191.09M in profits. Earnings per share was -22.49.
Revenue102.48M
Gross Profit95.16M
Operating Income-104.95M
Pretax Income-191.18M
Net Income-191.09M
EBITDA-145.65M
Earnings Per Share (EPS)-22.49
Cash Flow
In the last 12 months, operating cash flow was -151.61M and capital expenditures -532.00K, giving a free cash flow of -152.14M billion.
Operating Cash Flow-151.61M
Free Cash Flow-152.14M
Free Cash Flow per Share-9.18
Dividends & Yields
Sutro Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.57
52-Week Price Change305.09%
50-Day Moving Average31.84
200-Day Moving Average19.34
Relative Strength Index (RSI)54.40
Average Volume (3m)987.85K
Important Dates
Sutro Biopharma upcoming earnings date is Aug 10, 2026, TBA (Confirmed).
Last Earnings DateMay 14, 2026
Next Earnings DateAug 10, 2026
Ex-Dividend Date―
Financial Position
Sutro Biopharma as a current ratio of 2.01, with Debt / Equity ratio of -20.38%
Current Ratio2.01
Quick Ratio2.01
Debt to Market Cap0.00
Net Debt to EBITDA0.29
Interest Coverage Ratio-2.75
Taxes
In the past 12 months, Sutro Biopharma has paid -93.00K in taxes.
Income Tax-93.00K
Effective Tax Rate<0.01
Enterprise Valuation
Sutro Biopharma EV to EBITDA ratio is -0.38, with an EV/FCF ratio of -0.31.
EV to Sales0.55
EV to EBITDA-0.38
EV to Free Cash Flow-0.31
EV to Operating Cash Flow-0.32
Balance Sheet
Sutro Biopharma has $202.56M in cash and marketable securities with $13.63M in debt, giving a net cash position of $188.93M billion.
Cash & Marketable Securities$202.56M
Total Debt$13.63M
Net Cash$188.93M
Net Cash Per Share$11.40
Tangible Book Value Per Share-$15.59
Margins
Gross margin is 98.72%, with operating margin of -102.41%, and net profit margin of -186.45%.
Gross Margin98.72%
Operating Margin-102.41%
Pretax Margin-186.55%
Net Profit Margin-186.45%
EBITDA Margin-142.12%
EBIT Margin-149.26%
Analyst Forecast
The average price target for Sutro Biopharma is $50.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$50.50
Price Target Upside60.06% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast49.94%
EPS Growth Forecast44.76%